MX361925B - Medicamento inhalable que comprende tiotropio. - Google Patents
Medicamento inhalable que comprende tiotropio.Info
- Publication number
- MX361925B MX361925B MX2014007357A MX2014007357A MX361925B MX 361925 B MX361925 B MX 361925B MX 2014007357 A MX2014007357 A MX 2014007357A MX 2014007357 A MX2014007357 A MX 2014007357A MX 361925 B MX361925 B MX 361925B
- Authority
- MX
- Mexico
- Prior art keywords
- tiotropium
- formulation
- inhalable medicament
- percentages
- mdi
- Prior art date
Links
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940110309 tiotropium Drugs 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se refiere a una formulación para solución que comprende una sal de tiotropio, 12-20% de etanol, 0.1-1.5% de agua, 0.05-0.10% de ácido cítrico (u otro ácido orgánico) y un propelente de HFA, en donde los porcentajes son porcentajes en peso basados en el peso total de la formulación. La invención también provee un pMDI que comprende un envase que contiene la formulación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161577315P | 2011-12-19 | 2011-12-19 | |
| GBGB1200525.2A GB201200525D0 (en) | 2011-12-19 | 2012-01-13 | An inhalable medicament |
| PCT/EP2012/074690 WO2013092237A1 (en) | 2011-12-19 | 2012-12-06 | An inhalable medicament comprising tiotropium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007357A MX2014007357A (es) | 2014-08-21 |
| MX361925B true MX361925B (es) | 2018-12-19 |
Family
ID=45813952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007357A MX361925B (es) | 2011-12-19 | 2012-12-06 | Medicamento inhalable que comprende tiotropio. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9655969B2 (es) |
| EP (3) | EP3143998B1 (es) |
| JP (1) | JP5791166B2 (es) |
| KR (2) | KR20160111539A (es) |
| CN (1) | CN103998039A (es) |
| AR (1) | AR089302A1 (es) |
| AU (1) | AU2012358475B2 (es) |
| BR (1) | BR112014014535A2 (es) |
| CA (1) | CA2856047C (es) |
| CY (1) | CY1116142T1 (es) |
| DK (3) | DK3143998T3 (es) |
| EA (1) | EA028461B1 (es) |
| ES (3) | ES2602314T3 (es) |
| GB (1) | GB201200525D0 (es) |
| HK (2) | HK1198512A1 (es) |
| HR (1) | HRP20141176T1 (es) |
| HU (2) | HUE030983T2 (es) |
| IL (1) | IL232946A0 (es) |
| MX (1) | MX361925B (es) |
| PL (3) | PL2793886T3 (es) |
| PT (1) | PT2606891E (es) |
| RS (1) | RS53783B1 (es) |
| SI (1) | SI2606891T1 (es) |
| SM (1) | SMT201400192B (es) |
| TR (1) | TR201908429T4 (es) |
| TW (1) | TWI468187B (es) |
| UY (1) | UY34525A (es) |
| WO (1) | WO2013092237A1 (es) |
| ZA (2) | ZA201403041B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2515854B1 (en) | 2009-12-23 | 2014-03-19 | Chiesi Farmaceutici S.p.A. | Aerosol formualtion for COPD |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| JP6335798B2 (ja) | 2012-02-28 | 2018-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規噴射剤含有チオトロピウム製剤 |
| HK1212903A1 (zh) * | 2013-11-22 | 2016-06-24 | Teva Branded Pharmaceutical Products R & D, Inc. | 可吸入藥物 |
| CN104968328A (zh) * | 2013-11-22 | 2015-10-07 | 梯瓦优质制药产品研发股份有限公司 | 可吸入药物 |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| WO2017075018A1 (en) * | 2015-10-29 | 2017-05-04 | 3M Innovative Properties Company | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| EP3515439B1 (en) * | 2016-09-19 | 2021-12-15 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| US12220525B2 (en) | 2018-06-27 | 2025-02-11 | Kindeva Drug Deliver L.P. | Tiotropium formulation and inhaler |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| GB9026191D0 (en) | 1990-12-01 | 1991-01-16 | Harris Pharma Ltd | Breath actuated dispensing device |
| DK0616525T3 (da) | 1991-12-12 | 1996-01-08 | Glaxo Group Ltd | Medikamenter |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB2264238A (en) | 1992-05-29 | 1993-08-25 | Norton Healthcare Ltd | Medicament inhalor device |
| RO117414B1 (ro) | 1992-12-09 | 2002-03-29 | Jager Paul D Waterbury | Compozitie farmaceutica de aerosol in solutie |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| PT1131059E (pt) | 1998-11-13 | 2003-07-31 | Jago Res Ag | Po seco para inalacao |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| CA2387212A1 (en) | 1999-10-12 | 2001-04-19 | Kaken Pharmaceutical Co., Ltd. | Dry powder inhalation and a method for the preparation thereof |
| HU230804B1 (hu) | 2000-05-22 | 2018-06-28 | Chiesi Farmaceutici S.P.A | Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| US6553988B1 (en) | 2000-06-09 | 2003-04-29 | Norton Healthcare, Inc. | Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber |
| TR200402367T4 (tr) | 2000-10-12 | 2004-12-21 | Boehringer Ingelheim Pharma Gmbh& Co.Kg | Yeni tiotropyum içeren inhalasyon tozları |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| OA12403A (en) | 2000-10-12 | 2006-04-18 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament. |
| PT1243263E (pt) * | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
| DE10126924A1 (de) | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalationskapseln |
| US20030070679A1 (en) | 2001-06-01 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
| US6608055B2 (en) | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| EA005813B1 (ru) | 2001-06-22 | 2005-06-30 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Безводный кристаллический тиотропийбромид, способ его получения и его применение для получения лекарственного средства |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
| US7311894B2 (en) | 2002-03-28 | 2007-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations containing an anticholinergic |
| DE10214263A1 (de) | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum |
| GB0219511D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| RU2005122444A (ru) * | 2002-12-16 | 2007-01-27 | Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) | Композиции в виде содержащих тиотропий растворов с гидрофторуглеродом |
| US20050058606A1 (en) | 2002-12-16 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing HFC solution formulations |
| DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| EP1699435A4 (en) | 2003-09-18 | 2009-05-20 | Norton Healthcare Ltd | PARTICLE |
| US7968717B2 (en) | 2003-11-03 | 2011-06-28 | Boehringer Ingelhein International Gmbh | Crystalline anhydrate with anticholinergic efficacy |
| BRPI0415636A (pt) | 2003-11-03 | 2006-12-12 | Boehringer Ingelheim Int | anidrato cristalino com efeito anticolinérgico |
| SE0303570L (sv) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| AU2005221151A1 (en) | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| US20060079544A1 (en) | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| UA92732C2 (ru) * | 2005-02-25 | 2010-12-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтические аэрозольные композиции для ингаляторов под давлением с вымеренными дозами, которые содержат связующее соединение |
| RU2007144531A (ru) | 2005-05-02 | 2009-06-10 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Новые кристаллические формы тиотропийбромида |
| EP1881980B1 (en) | 2005-05-02 | 2012-08-22 | Boehringer Ingelheim International GmbH | Novel crystalline forms of tiotropium bromide |
| RU2418796C2 (ru) | 2005-06-15 | 2011-05-20 | Берингер Ингельхайм Интернациональ Гмбх | Способ получения новых солей тиотропия |
| EP1915158A1 (en) | 2005-08-06 | 2008-04-30 | Boehringer Ingelheim International GmbH | Use of tiotropium salts in the treatment of severe persistant asthma |
| US20070088030A1 (en) | 2005-10-10 | 2007-04-19 | Barbara Niklaus-Humke | Aerosol formulations for the inhalation of beta-agonists |
| DK1869035T4 (en) | 2005-12-19 | 2015-11-16 | Sicor Inc | HIS UNKNOWN CRYSTALLIC FORM OF THIOTROPIUM BROMIDE AND PROCEDURE FOR PREPARING THEREOF |
| EP1923393A1 (en) | 2006-11-17 | 2008-05-21 | Boehringer Ingelheim Pharma GmbH & Co. KG | Crystalline form of tiotropium bromide and urea |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| EP2201934A1 (en) | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| US8889213B2 (en) | 2009-01-26 | 2014-11-18 | Teva Pharmaceutical Industries Ltd. | Processes for coating a carrier with microparticles |
| ES2533535T3 (es) * | 2009-11-17 | 2015-04-10 | Cipla Limited | Soluciones para inhalación |
| EA023795B1 (ru) | 2010-10-12 | 2016-07-29 | Ивакс Фармасьютикалз Айэлэнд | Назальное распылительное устройство |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| GB201200504D0 (en) | 2011-12-19 | 2012-02-22 | Teva Branded Pharmaceutical Prod R & D Inc | An inhaler |
| JP6335798B2 (ja) | 2012-02-28 | 2018-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規噴射剤含有チオトロピウム製剤 |
-
2012
- 2012-01-13 GB GBGB1200525.2A patent/GB201200525D0/en not_active Ceased
- 2012-12-06 US US14/367,031 patent/US9655969B2/en active Active
- 2012-12-06 CN CN201280060763.4A patent/CN103998039A/zh active Pending
- 2012-12-06 HK HK14111996.5A patent/HK1198512A1/xx unknown
- 2012-12-06 ES ES12806382.3T patent/ES2602314T3/es active Active
- 2012-12-06 EP EP16185402.1A patent/EP3143998B1/en not_active Revoked
- 2012-12-06 ES ES16185402T patent/ES2728940T3/es active Active
- 2012-12-06 JP JP2014543943A patent/JP5791166B2/ja not_active Expired - Fee Related
- 2012-12-06 PL PL12806382T patent/PL2793886T3/pl unknown
- 2012-12-06 EA EA201491206A patent/EA028461B1/ru not_active IP Right Cessation
- 2012-12-06 KR KR1020167025194A patent/KR20160111539A/ko not_active Withdrawn
- 2012-12-06 MX MX2014007357A patent/MX361925B/es active IP Right Grant
- 2012-12-06 DK DK16185402.1T patent/DK3143998T3/da active
- 2012-12-06 BR BR112014014535A patent/BR112014014535A2/pt not_active Application Discontinuation
- 2012-12-06 HU HUE12806382A patent/HUE030983T2/en unknown
- 2012-12-06 PL PL16185402T patent/PL3143998T3/pl unknown
- 2012-12-06 HU HUE16185402 patent/HUE044647T2/hu unknown
- 2012-12-06 CA CA2856047A patent/CA2856047C/en not_active Expired - Fee Related
- 2012-12-06 AU AU2012358475A patent/AU2012358475B2/en not_active Ceased
- 2012-12-06 DK DK12806382.3T patent/DK2793886T3/en active
- 2012-12-06 EP EP12806382.3A patent/EP2793886B1/en not_active Revoked
- 2012-12-06 KR KR1020147017716A patent/KR101670564B1/ko not_active Expired - Fee Related
- 2012-12-06 WO PCT/EP2012/074690 patent/WO2013092237A1/en not_active Ceased
- 2012-12-06 TR TR2019/08429T patent/TR201908429T4/tr unknown
- 2012-12-06 HK HK15100893.1A patent/HK1200343A1/xx unknown
- 2012-12-12 DK DK12196725.1T patent/DK2606891T3/en active
- 2012-12-12 SI SI201230113T patent/SI2606891T1/sl unknown
- 2012-12-12 EP EP12196725.1A patent/EP2606891B1/en not_active Revoked
- 2012-12-12 RS RS20140691A patent/RS53783B1/sr unknown
- 2012-12-12 ES ES12196725.1T patent/ES2526685T3/es active Active
- 2012-12-12 PL PL12196725T patent/PL2606891T3/pl unknown
- 2012-12-12 PT PT121967251T patent/PT2606891E/pt unknown
- 2012-12-18 UY UY0001034525A patent/UY34525A/es not_active Application Discontinuation
- 2012-12-18 AR ARP120104795A patent/AR089302A1/es not_active Application Discontinuation
- 2012-12-19 TW TW101148516A patent/TWI468187B/zh not_active IP Right Cessation
-
2014
- 2014-04-25 ZA ZA2014/03041A patent/ZA201403041B/en unknown
- 2014-06-02 IL IL232946A patent/IL232946A0/en active IP Right Grant
- 2014-12-04 HR HRP20141176AT patent/HRP20141176T1/hr unknown
- 2014-12-19 CY CY20141101072T patent/CY1116142T1/el unknown
- 2014-12-22 SM SM201400192T patent/SMT201400192B/xx unknown
-
2015
- 2015-03-23 ZA ZA2015/01986A patent/ZA201501986B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX361925B (es) | Medicamento inhalable que comprende tiotropio. | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| MY183312A (en) | Pharmaceutical formulation | |
| WO2013091775A3 (de) | Verwendung von cyclohexanolderivaten als antimikrobielle wirkstoffe | |
| WO2012016845A3 (en) | Pharmaceutical formulation comprising a phosphodiesterase inhibitor | |
| PH12015500686A1 (en) | Nicotine composition | |
| MX2015010971A (es) | Derivado novedoso de pirazol. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| MX357619B (es) | Inhalador que comprende una composición que contiene tiotropio. | |
| WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
| WO2013021199A3 (en) | Eutectic mixture for pulmonary administration | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| IL229260A0 (en) | Preparations, methods and systems for respiratory administration of two or more active agents | |
| HK1221653A1 (zh) | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| IN2014DN01619A (es) | ||
| WO2012176138A3 (en) | Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine | |
| WO2013190497A3 (en) | Compositions and methods for treatment of inflammatory diseases of the lung | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| WO2012155226A8 (pt) | Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos | |
| UY32894A (es) | Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica | |
| WO2012149295A3 (en) | Methods of administering anatabine to treat autism spectrum disorders and seizure disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |